Knight Therapeutics Inc.
KHTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $87,271 | $107,358 | $88,076 | $96,864 |
| % Growth | -18.7% | 21.9% | -9.1% | – |
| Cost of Goods Sold | $58,290 | $62,527 | $53,210 | $56,512 |
| Gross Profit | $28,981 | $44,831 | $34,866 | $40,352 |
| % Margin | 33.2% | 41.8% | 39.6% | 41.7% |
| R&D Expenses | $6,242 | $6,281 | $4,786 | $7,365 |
| G&A Expenses | $0 | $15,814 | $12,219 | $10,741 |
| SG&A Expenses | $22,275 | $31,488 | $26,143 | $25,317 |
| Sales & Mktg Exp. | $0 | $15,674 | $13,924 | $14,576 |
| Other Operating Expenses | $0 | $10,731 | $9,474 | $10,630 |
| Operating Expenses | $28,518 | $48,500 | $40,403 | $43,312 |
| Operating Income | $464 | -$3,669 | -$5,537 | -$2,960 |
| % Margin | 0.5% | -3.4% | -6.3% | -3.1% |
| Other Income/Exp. Net | -$1,840 | -$11,941 | $5,138 | $10,835 |
| Pre-Tax Income | -$1,376 | -$15,610 | -$399 | $7,875 |
| Tax Expense | $1,346 | -$2,988 | -$2,584 | -$2,860 |
| Net Income | -$2,722 | -$12,622 | $2,185 | $10,735 |
| % Margin | -3.1% | -11.8% | 2.5% | 11.1% |
| EPS | -0.027 | -0.13 | 0.022 | 0.11 |
| % Growth | 79% | -693.6% | -80.1% | – |
| EPS Diluted | -0.027 | -0.13 | 0.02 | 0.11 |
| Weighted Avg Shares Out | 99,658 | 99,630 | 99,641 | 97,105 |
| Weighted Avg Shares Out Dil | 99,658 | 99,630 | 100,079 | 101,330 |
| Supplemental Information | – | – | – | – |
| Interest Income | $795 | $2,026 | $1,854 | $2,662 |
| Interest Expense | $1,700 | $2,374 | $1,756 | $2,447 |
| Depreciation & Amortization | $12,757 | $12,138 | $11,584 | $13,970 |
| EBITDA | $13,081 | -$1,098 | $12,941 | $24,292 |
| % Margin | 15% | -1% | 14.7% | 25.1% |